A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

This first-in-human study tests a new type of immunotherapy that uses tumor-infiltrating lymphocytes (TILs) — immune cells extracted from a patient's own tumor, grown in large numbers, and given back to the patient to fight the cancer — for people with metastatic colorectal cancer or pancreatic cancer that has spread. **You may be eligible if...** - You are 18 or older - You have metastatic colorectal or pancreatic cancer - You live close enough to a qualified hospital to receive treatment and monitoring - Your cancer has progressed despite prior treatments - You meet health and organ function requirements **You may NOT be eligible if...** - You have active autoimmune disease or are on immunosuppressive medications - You have brain metastases - You have serious heart, lung, or kidney problems - You have active infections Talk to your doctor to see if this trial is right for you.